Who Generates Higher Gross Profit? Regeneron Pharmaceuticals, Inc. or United Therapeutics Corporation

Regeneron vs. United Therapeutics: A Decade of Gross Profit Growth

__timestampRegeneron Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 201426145390001162636000
Thursday, January 1, 201537110190001396725000
Friday, January 1, 201645607330001526100000
Sunday, January 1, 201754751660001619600000
Monday, January 1, 201862767000001429100000
Tuesday, January 1, 201970812000001331200000
Wednesday, January 1, 202073772000001375200000
Friday, January 1, 2021136342000001563000000
Saturday, January 1, 2022106125000001789600000
Sunday, January 1, 2023113014000002070000000
Monday, January 1, 202412231500000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biotech Giants: Regeneron vs. United Therapeutics

In the competitive world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outperformed United Therapeutics Corporation in terms of gross profit. From 2014 to 2023, Regeneron's gross profit surged by over 330%, peaking at approximately $13.6 billion in 2021. In contrast, United Therapeutics saw a more modest increase of around 78%, reaching a high of $2.07 billion in 2023.

Key Insights

  • Regeneron's Growth: Regeneron's gross profit grew from $2.6 billion in 2014 to $11.3 billion in 2023, showcasing its robust market position.
  • United Therapeutics' Steady Climb: Despite a slower growth rate, United Therapeutics maintained a steady increase, highlighting its resilience in the biotech sector.

This financial narrative underscores the dynamic nature of the biotech industry, where innovation and strategic investments drive profitability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025